Fusion protein VT-GL-B3, coding gene thereof and applications thereof

A gene and encoding technology, applied in the fusion protein VT-GL-B3 and its encoding gene and application field, can solve problems such as abnormal cardiac conduction, achieve the effects of prolonging half-life, promoting tumor angiogenesis, and inhibiting tumor rescue response

Inactive Publication Date: 2014-05-28
INST OF BIOENG ACAD OF MILITARY MEDICAL SCI OF THE CHINESE
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The technical effect of this patented technology described in this patents is its ability to prevent or reduce the growth of new blood vessels (angioblasts) from growing on areas where they are needed most during medical procedures such as chemotherapies. It also targets specific types of cells like endothelial cell type A-4 lining vasculature, which plays an important role in promoting neovascularization and tissue regeneration processes after surgery.

Problems solved by technology

This patent describes various technical problem addressed in this patents relational research on developing novel therapy agents against diseased states like those associated with inflamed areas called arteriosclerosis and neovascular disease. Existing treatments either block specific targets involved in these processes or use multiple compounds simultanously.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion protein VT-GL-B3, coding gene thereof and applications thereof
  • Fusion protein VT-GL-B3, coding gene thereof and applications thereof
  • Fusion protein VT-GL-B3, coding gene thereof and applications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Embodiment 1, the preparation of VT-GL-B3 fusion protein

[0038] 1. Construction of recombinant plasmids

[0039] Insert the double-stranded DNA molecule shown in Sequence 2 of the sequence table between the NheI and NotI restriction sites of the pIRES2-EGFP vector to obtain the recombinant plasmid pIRES2-EGFP-VT-GL-B3. The schematic diagram of the structure of the recombinant plasmid pIRES2-EGFP-VT-GL-B3 is shown in figure 1 .

[0040] The double-stranded DNA molecule shown in Sequence 2 of the Sequence Listing was named VT-GL-B3 gene. The double-stranded DNA molecule shown in sequence 2 of the sequence listing encodes the protein shown in sequence 1 of the sequence listing. The protein shown in Sequence 1 of the sequence listing is named VT-GL-B3 fusion protein.

[0041] In sequence 1 of the sequence listing, amino acid residues 1 to 20 from the N-terminal are signal peptides, and amino acid residues 21-236 are VEGFR1D2R2D3 fragments (VEGFR1D2R2D3 fragments consist

Embodiment 2

[0056] Example 2, the biological activity of VT-GL-B3 mature peptide

[0057] 1. Affinity between VT-GL-B3 mature peptide and rhVEGF165

[0058] Biacore T200, CM5 sensor chip (Lot No.10148134), Amine Coupling Kit (Lot No.2057704), Human Antibody Capture Kit (Lot No.10137214), HBS-EP+buffer (10×) (Lot No.BCBJ0266V) Both were purchased from GE Healthcare.

[0059] Anti-Human IgG(Fc) Antibody is a component of Human Antibody Capture Kit (Lot No.10137214). HBS-EP + Buffer (10×) is diluted to 10 times volume with deionized water, which is HBS-EP + buffer solution.

[0060] 1. Anti-Human IgG (Fc) Antibody combined with the surface of CM5 sensor chip

[0061] (1) Embed the CM5 sensor chip into Biacore T200.

[0062] (2) Prepare Anti-Human IgG(Fc) Antibody solution with pH 5.0, 10mM sodium acetate buffer.

[0063] (3) According to the sample placement method in the Immobilization program setting, place the solution in the Amine Coupling Kit in the appropriate position of the Biaco

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a fusion protein VT-GL-B3, a coding gene thereof and applications thereof. The fusion protein is (a) or (b) or (c) as follows: (a) a protein formed by amino acid residues from the 21 site to the 468 site in the sequence 1 from the N end; (b) a protein formed by the amino acid sequence shown as the sequence 1; and (c) a derived protein obtained by subjecting the (a) or the (b) to substitution and/or deletion and/or addition of one or more of amino acid residues and related to angiogenesis. The invention also provides the applications of the fusion protein in preparation of medicines. The function of the medicines is at least one of the (I) to (V) as follows: (I) inhibition of vascular endothelial cell proliferation and/or migration; (II) inhibition of inhibit angiogenesis; (III) inhibition of tumor growth; (IV) treatment of cancer; and (V) treatment of angiogenesis-related diseases. The fusion protein, the coding gene thereof and the applications thereof have significant value for treatment of cancer and other angiogenesis-related diseases.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner INST OF BIOENG ACAD OF MILITARY MEDICAL SCI OF THE CHINESE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products